ReviewCentral-European journal of immunology2025
Modern biomarkers in IgA vasculitis with nephritis in children.
Review in Central-European journal of immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunoglobulin A (IgA) vasculitis (IgAV) is the most common form of vasculitis in the pediatric population. From 30% to 60% of children with IgAV are affected by the accumulation of deposits of IgA in the glomeruli and the development of nephropathy in the course of IgA vasculitis with nephritis (IgAVN). Besides well-known factors such as proteinuria or lower glomerular filtration rate (GFR), the need for the identification of early disease biomarkers was also pointed out. These biomarkers would enable us to predict the disease course in a non-invasive way and focus the therapy on risk stratification. We are searching for markers that will allow us to predict the progress of nephropathy in the course of IgAV or the severity of IgAVN. The aim of the study is to present the currently known biomarkers in IgAVN. We present the significance of GDIgA1, anti-GDIgA1, the immune complexes Gd-IgA1-anti-Gd-IgA1, Fc
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.